Onkologie. 2007:1(1):9-13

Chemotherapy of hormonally refractory prostatic carcinoma

Jozef Mardiak
Národný onkologický ústav, Bratislava

Prostatic carcinoma is one of the most frequent malignant diseases of males. Expectation of increasing incidence of this disease goes together with population growing old. Androgenic deprivation has been first line therapy of metastatic prostate cancer for more than 60 years. Most of the patients with disseminated disease become resistent to hormonal treatment after 2-3 years. Bones and lymphatic nodes are the most frequent site of metastasising.

Prostatic carcinoma has been considered to be a chemoresistant disease for long time. Recent positive results change the view for this disease.

Keywords: Key words: prostatic carcinoma, carcioma refractory to hormonal treatment, randomized trials, cytostatics. Key words MeSH: prostatic neoplasms – drug therapy; carcinoma – drug therapy; clinical trials; drug resistance.

Published: May 5, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mardiak J. Chemotherapy of hormonally refractory prostatic carcinoma. Onkologie. 2007;1(1):9-13.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2004. CA Cancer J Clin 2005; 55: 10-30. Go to original source... Go to PubMed...
    2. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71: 1098-1109. Go to original source...
    3. Raghavan D, Koczwara B, Javle M. Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Cancer 1997; 33: 566-574. Go to original source... Go to PubMed...
    4. Smith DC, Dunn RL, Strawdweman MS, Pienta KJ. Change in serum prostate specific antigen as a marker of response to cytotoxic therapy for hormone refractory prostate cancer. J Clin Oncol 1998; 16: 1835-1843. Go to original source... Go to PubMed...
    5. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendation from the Prostate Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-3467. Go to original source... Go to PubMed...
    6. Tanock, IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant: a Canadian randomized trial with palliative end points. J Clin Oncol 1966, 14: 1756-1764. Go to original source... Go to PubMed...
    7. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the CLGB 9182 study. J Clin Oncol 1999; 17: 2506-2513. Go to original source... Go to PubMed...
    8. Albrecht W, Van Poppel H, Horenblas S, et al.Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. Br J Cancer 2004; 90: 100-105. Go to original source... Go to PubMed...
    9. Hudes G, Einhorn L, Ross E, et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 1999; 17: 3160-3166. Go to original source... Go to PubMed...
    10. Petrylak DP, Tangen CM, Hussain MA, et al. Docetaxel and Estramustine versus Mitoxantrone and Prednisone in Men with Androgen Independent Prostate Cancer: Results of Southwest Oncology Group Intergroup Protocol 99-16. Ann Meet Am Soc Clin Oncol, San Antonio, 2004.
    11. de Wit R., Eisenberger MA, Tannock I, et al. A multicenter comparison of docetaxel given weekly or every three weeks + prednisone with mitoxantrone + prednisone in patients with hormone-refractory prostate cancer:Study TAX-327. Ann Meet Am Soc Clin Oncol, San Antonio, 2004.
    12. Saad F, Gleasin DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. Zoledronic Acid Prostate Cancer Study Group. JNCI 2004; 96: 879-882. Go to original source... Go to PubMed...
    13. Winquist E, Berry S. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. JNCI 2004; 96: 1183-1184. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.